4.Moderna and Merck shares soar on mRNA cancer vaccine
Moderna and Merck shares soar on mRNA cancer vaccine. Add Axios as your preferred source to.
Moderna and Merck shares soar on mRNA cancer vaccine. Add Axios as your preferred source to.
Article outline
- What happened
- What comes next
- The key numbers
- Background
- The bottom line
Key points
- While Merck shares closed up 12.6%, but Wall Street has already responded enthusiastically, with shares of Moderna surging 177% Wednesday.
- Political backlash after the pandemic – including the Trump administration pulling almost $500 million in federal funding for mRNA research – raised questions regarding the field's long-term prospects.
- The major picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined post-pandemic.
- The COVID company now cancer, Moderna president Stephen Hoge informed Axios.
- "This is a landmark moment, " TD Cowen analysts wrote in an investor note.
Meanwhile, the customized therapy, which could see a commercial launch next year, could additionally be adapted for other cancers of the kidney, bladder and pancreas.
Meanwhile, the major picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined post-pandemic. The firm this month additionally won Food and Drug Administration approval for a new mRNA seasonal flu vaccine.
"People will experience this as. The COVID company now cancer, " Moderna president Stephen Hoge informed Axios. "But for those of us that live in it, it's like the cancer company that pivoted on a dime to help with COVID has pivoted back and really finally come home."
Driving the news: The experimental therapy, called intismeran, was tested in combination with Merck's cancer drug Keytruda in more than 1, 100 patients with high-risk melanoma that had been surgically removed.
In practice, the combination demonstrated a "clinically meaningful improvement" over treating the skin cancers with Keytruda alone.
For context, the mRNA-based drugs essentially train the immune system to find mutations in a patient that cause tumors. That's a contrast to chemotherapy. It damages or destroys cancer cells.
"We may be entering an era where a patient's individual tumor biology can be used to design a therapy specifically for them, " William Soliman, founder and CEO of the Accreditation Council for Medical Affairs, remarked in an email.
In practice, the latest: The full results of the trial will be published at an upcoming medical gathering.
"This is a landmark moment, " TD Cowen analysts wrote in an investor note. "We view the result as a significant validation of the. Platform."
Between the lines: The safety profile of the combination treatment was consistent with earlier studies and indicated no new risks.
In practice, the findings indicated early cancers might be treated more aggressively than with prior treatments that were more toxic to the body, Hoge stated.
What we're watching: Whether the potential success of an mRNA-based cancer therapy could support lift the bigger cloud hanging over the technology.
For context, the FDA initially refused to review Moderna's mRNA flu vaccine before changing course.
"I do hope that this will move people away from pigeonholing mRNA as a vaccine platform, or maybe even more incorrectly, tying it to the things they didn't like about the pandemic era that had nothing to do with the technology, " Hoge remarked.
"I hope this starts to move us past that because it is, we think, a transformational moment in cancer."
For now, 4.Moderna and Merck shares soar on mRNA cancer vaccine remains the part of the story worth watching, and further updates are likely as more details are confirmed.




